Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Innovent Biologics HK$4.65 billion share placement
Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in…
Nurix Therapeutics $209 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of…
BioNTech $511.5 million share offering and rights offering
Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of…
Berkeley Lights $204.9 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of…
Atreca $125 million stock offering
Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered…
InflaRx $50 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its…
Inventiva $108 million U.S. IPO and Nasdaq listing
Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S…
Centogene $49 million follow-on offering
Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting…
Revolution Medicines $179.4 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of…
Ocumension Therapeutics HK$1.55 billion IPO and HKEX listing
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock…